M-DIENOGEST DIN 02543613
Health Canada record
| Active ingredient(s) | DIENOGEST 2 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | G03DB08 DIENOGEST |
| Original market date | 23-Apr-2024 |
| Current status date | 23-Apr-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Mantra Pharma Inc. — licence 101740, currently licensed, last inspection rating C (2023-05-10).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DIENOGEST
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02493055 | ASPEN-DIENOGEST | ASPEN PHARMACARE CANADA INC. | Tablet | DIENOGEST 2 MG | Marketed |
| 02567245 | BIO-DIENOGEST | BIOMED PHARMA | Tablet | DIENOGEST 2 MG | Approved |
| 02569205 | DIENOGEST | SANIS HEALTH INC | Tablet | DIENOGEST 2 MG | Approved |
| 02498189 | JAMP DIENOGEST | JAMP PHARMA CORPORATION | Tablet | DIENOGEST 2 MG | Marketed |
| 02551683 | MAR-DIENOGEST | MARCAN PHARMACEUTICALS INC | Tablet | DIENOGEST 2 MG | Marketed |
| 02566117 | NRA-DIENOGEST | NORA PHARMA INC | Tablet | DIENOGEST 2 MG | Approved |
| 02374900 | VISANNE | BAYER INC | Tablet | DIENOGEST 2 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 32243 | 2023-12-01 | Abbreviated New Drug Submission (ANDS) |
International API supply for DIENOGEST
2 valid EDQM Certificates of Suitability from 2 holders. 7 active FDA Drug Master Files.
Request a quote for M-DIENOGEST